Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Recher

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Science Translational Medicine|July 24, 2024
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo modelsClement Larrue, Sarah Mouche, Paolo Angelino, et al.
Haematologica|February 17, 2022
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemiasRosa Paolillo, Mathias Boulanger, Pierre Gâtel, et al.
Oncotarget|April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changesRaynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
Haematologica|April 22, 2011
TET2 mutations in secondary acute myeloid leukemias: a French retrospective studyOlivier Kosmider, Eric Delabesse, Véronique Mansat de Mas, et al.
Blood|December 18, 2012
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experienceMathilde Lamarque, Sophie Raynaud, Raphael Itzykson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid LeukemiaMarina Konopleva, Michael J Thirman, Keith W Pratz, et al.
Hemasphere|February 14, 2025
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantationSophie Le Grand, Juliette Villemonteix, Etienne Daguindau, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|June 4, 2016
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Science Translational Medicine|July 24, 2024
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo modelsClement Larrue, Sarah Mouche, Paolo Angelino, et al.
Haematologica|February 17, 2022
The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemiasRosa Paolillo, Mathias Boulanger, Pierre Gâtel, et al.
Oncotarget|April 11, 2015
Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changesRaynier Devillier, Véronique Mansat-De Mas, Veronique Gelsi-Boyer, et al.
Plos One|October 1, 2020
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidinePierre Bories, Naïs Prade, Stéphanie Lagarde, et al.
Haematologica|April 22, 2011
TET2 mutations in secondary acute myeloid leukemias: a French retrospective studyOlivier Kosmider, Eric Delabesse, Véronique Mansat de Mas, et al.
Blood|December 18, 2012
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experienceMathilde Lamarque, Sophie Raynaud, Raphael Itzykson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid LeukemiaMarina Konopleva, Michael J Thirman, Keith W Pratz, et al.
Hemasphere|February 14, 2025
HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantationSophie Le Grand, Juliette Villemonteix, Etienne Daguindau, et al.
Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.
Blood|June 4, 2016
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapyRuxanda Moschoi, Véronique Imbert, Marielle Nebout, et al.
Pageof 14